ATCF (Azole Therapy in Cystic Fibrosis)

PHASE2CompletedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

June 30, 2014

Primary Completion Date

October 31, 2015

Study Completion Date

November 30, 2015

Conditions
Cystic FibrosisAspergillus Infections
Interventions
DRUG

Itraconazole/voriconazole

The two treatments will be administered orally for 6 months One doage of treatment permitted based on plasma levels will be performed after two weeks of treatment.

Trial Locations (15)

13015

Hôpital Nord - Pneumology, Marseille

31059

Pédiatrie - Pneumologie, Allergologie - Hôpital des enfants, Toulouse

33000

Pediatric penumologic - Groupe hospitalier de Pellegrin, Bordeaux

35000

CRCM - Hôpital Sud, Rennes

Pneumology - Hôpital Pontchaillou, Rennes

49033

CRCM adulte - Centre Robert Debré, Angers

Pediatry - Centre Robert Debré, Angers

54577

Pneumologie Infantile - Hôpital des enfants, Nancy

56017

Pneumology - CH Bretagne-Atlantique, Vannes

59037

Service de Pneumologie-Immuno-Allergologie / Hôpital Calmette, Lille

67098

CRCM Pédiatrique - Hôpital de Hautepierre, Strasbourg

69500

Pneumology pediatric - Hôpital Femme-Mère-Enfants, Bron

80054

CRCM Adulte et Pédiatrie - Hôpital Nord, Amiens

94000

CRCM - Pediatry - CHI Créteil, Créteil

M23 9LT

Manchester Adult Cystic Fibrosis Centre - University Hospital of South Manchester, Manchester

All Listed Sponsors
lead

Rennes University Hospital

OTHER

NCT01576315 - ATCF (Azole Therapy in Cystic Fibrosis) | Biotech Hunter | Biotech Hunter